C. Seynaeve

发表

BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.

Harry J de Koning, Madeleine M A Tilanus-Linthorst, Mieke Kriege, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?

C. Brekelmans, C. Seynaeve, 2006, The Lancet. Oncology.

Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.

H. Meijers-Heijboer, M. Hooning, S. Verhoef, 2015, Journal of the National Cancer Institute.

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

M. Adank, H. V. van Doorn, M. Kriege, 2016, British Journal of Cancer.

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

A. Sieuwerts, E. Berns, A. Hollestelle, 2015, Journal of Cancer Research and Clinical Oncology.

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study

R. Tollenaar, N. Aaronson, M. Hooning, 2015, Familial Cancer.

A metastasis of an adenocarcinoma in a BRCA1 mutation carrier, a diagnostic problem not solved by morphology alone.

W. Dinjens, M. D. den Bakker, V. Kuenen-Boumeester, 2004, Human pathology.

Occult cancer in the fallopian tube in patients with a BRCA-1 germline mutation.

C. Burger, A. Ansink, C. Seynaeve, 2001, Gynecologic oncology.

[Practice guideline 'Diagnostic techniques for soft tissue tumours and treatment of soft tissue sarcomas (revision)'].

W. Molenaar, A. V. van Geel, P. Hogendoorn, 2005, Nederlands tijdschrift voor geneeskunde.

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy.

C. Seynaeve, F. D. De Vos, T. Middelburg, 2014, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

Ecthyma gangrenosum caused by Pseudomonas aeruginosa in a patient with astrocytoma treated with chemotherapy

C. Seynaeve, F. Vos, T. Middelburg, 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.

Victoria L. Cafourek, S. Cross, M. Beckmann, 2011, Journal of the National Cancer Institute.

Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.

M. Adank, M. Kriege, R. Zweemer, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

V. Pankratz, F. Couch, B. Bonanni, 2012, British Journal of Cancer.

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

Patrick Neven, Päivi Heikkilä, Giu-Cheng Hsu, 2011, Human molecular genetics.

Primitive neuroectodermal tumor of the cervix uteri: a case report -- changing concepts in therapy.

C. Burger, A. Snijders-Keilholz, P. Ewing, 2005, Gynecologic oncology.

An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers

B. Karlan, S. Buys, Sung-Won Kim, 2016, Breast Cancer Research and Treatment.

Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant

L. Koppert, W. Dinjens, P. Diest, 2017, Modern Pathology.

BC patients carrying the germline CHEK 2 1100 delC mutation mainly develop estrogen receptor ( ER )-positive

A. Sieuwerts, M. M. Gelder, E. Berns, 2015 .

Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer

H. D. de Koning, J. Klijn, R. Tollenaar, 2006, Breast Cancer Research and Treatment.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Hein Putter, Christos Markopoulos, Annette Hasenburg, 2011, The Lancet.

Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.

J. Klijn, M. Piccart, L. Mauriac, 2000, Journal of the National Cancer Institute.

A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients

Jaana M. Hartikainen, Kristen S Purrington, A. Børresen-Dale, 2015, BMC Cancer.

No evidence that GATA3 rs570613 SNP modifies breast cancer risk

K. Czene, P. Hall, V. Pankratz, 2009, Breast Cancer Research and Treatment.

FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium

Kristen S Purrington, P. Fasching, A. Ashworth, 2014, British Journal of Cancer.

COPD in cancer patients: higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient.

J. Coebergh, M. Janssen-Heijnen, L. V. van de Poll-Franse, 2007, European journal of cancer.

Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer

J. Klijn, R. Tollenaar, H. Peterse, 2006, Breast Cancer Research and Treatment.

Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Breast.

Survival in hereditary breast cancer associated with germline mutations of BRCA2.

J. Klijn, P. Devilee, C. Seynaeve, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.

J. Klijn, E. Berns, P. Devilee, 2001, European journal of cancer.

Passive coping and psychological distress in women adhering to regular breast cancer surveillance

H. Duivenvoorden, A. Tibben, J. Klijn, 2007, Psycho-oncology.

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial

H. Putter, C. Seynaeve, J. Bartlett, 2013, British Journal of Cancer.

Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study

P. V. van Diest, A. Jager, C. Seynaeve, 2015, PloS one.

Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2007, European journal of cancer.

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2001, The New England journal of medicine.

Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.

J. Klijn, C. Seynaeve, A. V. D. van den Ouweland, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and prognostic factors in BRCA1-associated breast cancer.

J. Klijn, H. Meijers-Heijboer, C. Seynaeve, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pelvic high-grade serous carcinoma in BRCA1 and BRCA2 mutation carriers

M. Adank, M. Kriege, R. Zweemer, 2013 .

Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.

C. Gundy, C. Seynaeve, S. Linn, 2010, Critical reviews in oncology/hematology.

Tailoring breast cancer therapy to genetic status

C. Brekelmans, C. Seynaeve, 2005, The Lancet.

Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.

J. Klijn, C. Seynaeve, A. V. D. van den Ouweland, 2004, European journal of cancer.

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

A Hollestelle, J. Martens, A. Sieuwerts, 2014, British Journal of Cancer.

Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.

M. Hooning, A. Jager, C. Seynaeve, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant

M. Schutte, R. Tollenaar, P. Devilee, 2004, Journal of Medical Genetics.

Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer

I H Kunkler, C. Seynaeve, G. Kerr, 2014, British Journal of Cancer.

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.

J. Blay, M. van Glabbeke, C. Seynaeve, 2004, European journal of cancer.

Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.

H. Putter, C. Seynaeve, J. Nortier, 2018, European journal of cancer.

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.

C. Seynaeve, J. Nortier, H. van Tinteren, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.

C. Seynaeve, J. Verweij, A. Sparreboom, 2004, European journal of cancer.

Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

H. Putter, C. Seynaeve, J. Nortier, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.

M. Adank, M. Kriege, R. Zweemer, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

OUTCOME OF BRCA1- COMPARED WITH BRCA2-ASSOCIATED OVARIAN CANCER: A NATIONWIDE STUDY IN THE NETHERLANDS

M. Adank, M. Kriege, R. Zweemer, 2017 .

Pelvic high-grade serous carcinoma in BRCA1 and BRCA2 mutation carriers

M. Adank, M. Kriege, R. Zweemer, 2013 .

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer

E. Berns, C. Seynaeve, E. Berns, 2010, British Journal of Cancer.

Self‐reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side‐study

C. Gundy, C. Seynaeve, S. Linn, 2012, Psycho-oncology.

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.

M. Schutte, R. Tollenaar, P. Devilee, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

A. Wymenga, H. Tinteren, M. Hamaker, 2014, Breast.

Peer Reviewed Title

B. Bonanni, O. Olopade, B. Karlan, 2012 .

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.

C. Seynaeve, J. Nortier, B. V. van Munster, 2013, Breast.

[CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].

M. Adank, J. Oosterwijk, F. Hes, 2015, Nederlands tijdschrift voor geneeskunde.

Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?

J. Klijn, C. Seynaeve, H. Duivenvoorden, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy.

J. Klijn, C. Seynaeve, H. Duivenvoorden, 2007, European journal of cancer.

Impact of screening for breast cancer in high-risk women on health-related quality of life